Clinical Trial Update: A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled trial evaluating LCQ908 in familial chylomicronemia syndrome has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• LCQ908

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Familial Chylomicronemia Syndrome (FCS) | Phase 3 | Status: COMPLETED | Results posted: 2015-06-03